Rocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis; Lasting improvement seen for patients receiving anti-OX40 antibody rocatinlimab compared with placebo.

Press/Media

Period15 Dec 2022

Media coverage

1

Media coverage

  • TitleRocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis; Lasting improvement seen for patients receiving anti-OX40 antibody rocatinlimab compared with placebo.
    Media name/outletPhysician's Briefings
    Country/TerritoryUnited States
    Date15/12/22
    PersonsEmma Guttman
View all 1
View less